David E. I. Pyott

President at International Council of Ophthalmology Foundation

David E. I. Pyott

David E. I. Pyott

President at International Council of Ophthalmology Foundation

Overview
Career Highlights

International Council of Ophthalmology Foundation
Allergan Sales LLC
Allergan Specialty Therapeutics, Inc.

RelSci Relationships

4232

Number of Boards

34

Birthday

1954

Age

67

Number of Awards

6

Contact Data
Trying to get in touch with David E. I. Pyott? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals David E. I. Pyott likely has professional access to. A relationship does not necessarily indicate a personal connection.

Former Chief Financial Officer at Allergan Specialty Therapeutics, Inc.

Relationship likelihood: Strong

Dean Emeritus at Johns Hopkins Bloomberg School of Public Health

Relationship likelihood: Strong

President & Chief Executive Officer at Sarepta Therapeutics, Inc.

Relationship likelihood: Strong

Chairman, President & Chief Executive Officer at The Allergan Foundation

Relationship likelihood: Strong

Former Executive Vice President, Finance & Business Development & Chief Financial Officer at Allergan, Inc.

Relationship likelihood: Strong

Former President & Chief Executive Officer at Alcon, Inc.

Relationship likelihood: Strong

Chief Executive Officer at Alnylam Pharmaceuticals, Inc.

Relationship likelihood: Strong

Director at Glaucoma Research Foundation

Relationship likelihood: Strong

Former Chief Executive Officer at Avery Dennison Corporation

Relationship likelihood: Strong

Chairman of the Board, President & Chief Executive Officer at Avery Dennison Corporation

Relationship likelihood: Strong

Paths to David E. I. Pyott
Potential Connections via
Relationship Science
You
David E. I. Pyott
President at International Council of Ophthalmology Foundation
Education
Master of Arts

The University of Edinburgh, founded in 1583, is a public research university in Edinburgh, the capital of Scotland. It was the fourth university to be established in Scotland and the sixth in the United Kingdom, and is one of the most prestigious universities in the world. Edinburgh receives approximately 47,000 applications every year, making it the third most popular university in the UK by volume of applicants. Entrance is intensely competitive, with offer chances of 27% in the 2010-2011 admissions cycle. The university is deeply embedded in the fabric of the city, with many of the buildings in the historic Old Town belonging to the university.

Diploma in International & European Law

The University of Amsterdam is one of the world’s intellectual hubs with a rich history dating back to 1632

Career History
President & Chief Executive Officer
1998 - 2015

Allergan, Inc. operated as a global healthcare company. It engaged in the development and commercialization of specialty pharmaceutical, medical device ,and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention, urological, and other specialty markets. The company was founded by Gavin S. Herbert in 1950 and headquartered in Irvine, CA.

President & Chief Executive Officer
1992 - 1995
General Manager
Prior
Boards & Committees
Independent Director
2021 - Current

Pliant Therapeutics, Inc. engages in the business of developing and commercializing novel therapies for fibrotic diseases. It offers product discovery engine. The company is pursuing drug development programs for a range of fibrotic diseases, focusing on tissue-specific integrin modulation and TGF-ß1 signaling inhibition. Pliant Therapeutics was founded by Bradley Backes, Bill De Grado, Hal Chapman, and Dean Sheppard in June 2015 and is headquartered in South San Francisco, CA.

Chairman, Board of Directors
2016 - Current

Bioniz Therapeutics, Inc. operates as a biopharmaceutical firm. The firm engages in the development of peptide therapeutics that selectively and simultaneously inhibit multiple cytokines for the treatment of immune diseases and cancer. The company was founded by Yutaka Tagaya and Nazli Azimi in 2009 and is headquartered in Irvine, CA.

Member, Board of Directors
2016 - Current

About BioMarin BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; KUVAN® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase III clinical development for the treatment of MPS IVA, PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU, BMN-701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase I/II clinical development for the treatment of Pompe disease, and BMN-673, a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase I/II clinical development for the treatment of genetically-defined cancers and BMN-111, a modified C-natriuretic peptide, which is currently in Phase I clinical development for the treatment of achondroplasia.

Trustee
2019 - Current

California Institute of Technology provides education focusing on science, engineering, academia, business, and public service. The company was founded in 1891 and it is headquartered in Pasadena, CA.

Member of the Governing Board
2015 - Current

London Business School (LBS) is an international business school and a constituent college of the federal University of London, located in central London, England, United Kingdom, beside Regent's Park. It was established in 1964, after the Franks Report recommended the establishment of two business schools, as part of existing universities (London Business School and Manchester Business School), but with considerable autonomy.

Member, Advisory Board
2002 - Current
Non-Profit Donations & Grants

Learn how non-profit organizations benefit from RelSci
$1,000 - $4,999
2016

Glaucoma Research Foundation is a nonprofit company headquartered in San Francisco, CA. The firm provides education services. It was founded by Adrienne L. Graves. Thomas M. Brunner is the current CEO of the firm.The company says this about itself: Glaucoma Research Foundation (GRF) is a national non-profit organization dedicated to finding a cure for glaucoma. For more than 40 years, Glaucoma Research Foundation has worked to advance sight-saving research and provide essential educational resources for patients. It funds critical research into glaucoma treatment, vision restoration, and a cure for glaucoma. It is also the leading source of information for glaucoma patients and their families.

$10K - $25K
2010

THE ORGANIZATION IS DEDICATED TO THE SUPPORT OF PROGRAMS THAT WILL ELEVATE THE LEVEL OF OPHTHALMIC EDUCATION WORLDWIDE.

$5,000 - $10K
2010

TO ADVANCE AAO'S PRIORITY PROGRAMS IN EDUCATION, QUALITY AND DATA SCIENCE, AND PUBLIC SERVICE.

Political Donations
$10K
2015

Director at Acreage Holdings

$10K
2014

Director at Acreage Holdings

$2,000
2014

Former Representative at Office of the Representative from California's 45th District, Mimi Walters

Transactions
Details Hidden

Apollo Endosurgery, Inc. (Inactive), CPMG, PTV Sciences LP, Novo Ventures 1 A/S, H.I.G. BioHealth Partners LLC purchase Allergan, Inc. /Obesity Intervention Business from Allergan, Inc.

Investments
Details Hidden

Mellon Medical BV manufactures and develops surgical suturing devices. The firm’s suturing device, the Switch, is designed for surgeons who perform the challenging operations and can easily be rotated in the hand because of its pencil-like shape. The company was founded in April 2013 by Mark Vrancken Peeters and is headquartered in Nijmegen, the Netherlands.

Details Hidden

Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that focuses on the discovery, clinical development, and commercialization of aesthetics and medical dermatology. Its products include Topical by Design platform for patients with inflammatory skin diseases and other dermatologic and aesthetic conditions through SNA-120, SNA-125, and SNA-001. The company was founded by Todd Harris and Frederick C. Beddingfield III on July 27, 2010 and is headquartered in Westlake Village, CA.

Details Hidden

Bioniz Therapeutics, Inc. operates as a biopharmaceutical firm. The firm engages in the development of peptide therapeutics that selectively and simultaneously inhibit multiple cytokines for the treatment of immune diseases and cancer. The company was founded by Yutaka Tagaya and Nazli Azimi in 2009 and is headquartered in Irvine, CA.

Public Holdings
Restricted data only for RelSci Professional users.
Awards & Honors
Rank #80
2014
Chief Executive Magazine - Wealth Creators
Rank #45
2014
Fortune Magazine - Business Person of the Year
Rank #4
2014
Harvard Business Review - 100 Best-Performing CEOs in the World
Events
Attendee
Washington, DC, United States
2010 Wall Street Journal CEO Council Annual Meeting

Wall Street Journal’s annual CEO Council meeting released specific priorities that both government and business must address to restore global growth and to increase public confidence in business. The plans voted by CEO Council members as the top two priorities each focused on job creation – leading with a call to foster global trade, followed by a call for the president to encourage a competitive business environment and be an advocate for business in general. The CEO Council worked together in task force sessions charged with identifying and ranking the most urgent priorities. Leading subject-matter experts provided key perspectives and information for the discussion, which focused on five key topics: fresh approaches to energy and the environment, the future of global finance, creating sustainable jobs, restoring confidence in business and next step for healthcare.

Other Affiliations

David E. I. Pyott is affiliated with Allergan, Inc., Sandoz Nutrition Corp., Sandoz Nutrition SA, Serica Technologies, Inc., Vicept Therapeutics, Inc., Allergan Specialty Therapeutics, Inc., SkinMedica, Inc., The Allergan Foundation, Edwards Lifesciences LLC, Novartis AG, International Council of Ophthalmology Foundation, Sienna Biopharmaceuticals, Inc., Avery Dennison Corporation, Allergan Sales LLC, Pliant Therapeutics, Inc., Bioniz Therapeutics, Inc., BioMarin Pharmaceutical, Inc., Alnylam Pharmaceuticals, Inc., Koninklijke Philips NV, SVB Leerink LLC, Sienna Biopharmaceuticals, Inc., Alliance for Eye & Vision Research, Allergan, Inc., Serica Technologies, Inc., Edwards Lifesciences Corp., Avery Dennison Corporation, Novartis AG, Pacific Mutual Holding Company, Pacific LifeCorp., Rani Therapeutics LLC, MAP Pharmaceuticals, Inc., Allergan Sales LLC, Philips Electronics North America Corporation, California Institute of Technology, University of London - London Business School, American Academy of Ophthalmology Foundation, Foundation of The American Academy of Ophthalmology, The David & Julianna Pyott Foundation, The International Council of Ophthalmology, International Council of Ophthalmology Foundation, Biotechnology Innovation Organization, American Academy of Ophthalmology, Glaucoma Research Foundation, Pan-American Ophthalmological Foundation, The Allergan Foundation, California Healthcare Institute, Chapman University, Cosmetic Surgery Foundation, Inc., University of California - Irvine School of Management

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by David E. I. Pyott. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of David E. I. Pyott's profile does not indicate a business or promotional relationship of any kind between RelSci and David E. I. Pyott.